We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”

Learn more about it by watching THIS NOW.

ALIM Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 31.40%

Insider Buying (Last 12 Months): $4,346,041.70

Insider Selling (Last 12 Months): $0.00

Alimera Sciences Insider Trading History Chart

Alimera Sciences Share Price & Price History

^$3.65

▲ +0.17 (4.89%)

As of 05/3/2024 01:00 AM ET

Days: 30 | 90 | 365

Elon to Transform U.S. Economy?

From Porter & Company | Ad

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

Alimera Sciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/14/2023	Caligan Partners Lp	Major Shareholder	Buy	579,000	$3.39	$1,962,810.00	16,835,154
5/17/2023	Adam Morgan	Director	Buy	1,401,901	$1.70	$2,383,231.70	1,659,654
3/24/2023	Alto Investors Lp Palo	Major Shareholder	Sell	200,919	$1.56	$313,433.64
2/8/2022	Stanley Morgan	Major Shareholder	Sell	250,000	$4.55	$1,137,500.00
12/15/2021	Richard S. Eiswirth, Jr.	CEO	Buy	484	$4.50	$2,178.00
12/2/2021	Richard S. Eiswirth, Jr.	CEO	Buy	5,000	$4.89	$24,450.00
11/5/2021	Richard S. Eiswirth, Jr.	CEO	Buy	1,400	$5.50	$7,700.00
11/3/2021	James R. Largent	Director	Buy	10,000	$4.31	$43,100.00
11/3/2021	John Philip Jones	CFO	Buy	5,000	$4.08	$20,400.00
11/3/2021	Richard S. Eiswirth, Jr.	CEO	Buy	28,005	$4.45	$124,622.25

Claim Your Complimentary Bitcoin Reward

From Crypto Swap Profits | Ad

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Secure Your Spot Now

SEC Filings (Institutional Ownership Changes) for Alimera Sciences (NASDAQ:ALIM)

99.83% of Alimera Sciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Alimera Sciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/2/2024	Fifth Lane Capital LP	21,238	$83K	0.1%	N/A	0.041%
2/13/2024	Stonepine Capital Management LLC	3,999,459	$17.28M	7.5%	+0.4%	7.630%
2/12/2024	AIGH Capital Management LLC	2,226,068	$9.62M	3.8%	-6.2%	4.247%
2/9/2024	Worth Venture Partners LLC	556,642	$2.41M	1.3%	-6.2%	1.062%
11/15/2023	Worth Venture Partners LLC	593,709	$1.84M	1.1%	N/A	1.133%
11/14/2023	Stonepine Capital Management LLC	3,983,686	$12.35M	4.1%	N/A	7.600%
11/13/2023	AIGH Capital Management LLC	2,372,572	$7.36M	3.5%	N/A	4.526%
8/14/2023	Perritt Capital Management Inc.	10,000	$29K	0.0%	-44.4%	0.114%
8/11/2023	Velan Capital Investment Management LP	1,659,654	$4.85M	4.5%	+543.9%	18.838%
2/16/2023	Caligan Partners LP	478,777	$1.30M	1.0%	N/A	6.840%
11/15/2022	Perritt Capital Management Inc.	18,000	$91K	0.1%	-34.3%	0.257%
5/12/2022	Healthcare of Ontario Pension Plan Trust Fund	250,000	$1.40M	0.0%	N/A	3.575%
2/10/2022	AIGH Capital Management LLC	497,639	$2.55M	0.8%	-0.7%	7.173%
11/15/2021	Ensign Peak Advisors Inc	19,151	$81K	0.0%	N/A	0.276%
11/12/2021	Renaissance Technologies LLC	141,588	$0.60M	0.0%	-1.9%	2.041%
10/22/2021	Optimum Investment Advisors	8,108	$34K	0.0%	+170.3%	0.117%
8/25/2021	Marshall Wace LLP	13,086	$0.12M	0.0%	-50.6%	0.189%
8/17/2021	Bridgeway Capital Management LLC	38,300	$0.35M	0.0%	+6.5%	0.554%
8/16/2021	PDT Partners LLC	17,723	$0.16M	0.0%	+50.2%	0.256%
8/16/2021	Morgan Stanley	428,109	$3.90M	0.0%	+0.7%	6.190%
8/16/2021	Diametric Capital LP	30,842	$0.28M	0.2%	+17.1%	0.446%
8/16/2021	Marshall Wace LLP	13,086	$0.12M	0.0%	-50.6%	0.189%
8/13/2021	Knott David M	38,226	$0.35M	0.1%	-34.2%	0.553%
8/13/2021	Geode Capital Management LLC	25,091	$0.23M	0.0%	+14.7%	0.363%
8/13/2021	Vanguard Group Inc.	146,863	$1.34M	0.0%	+16.6%	2.124%
8/12/2021	Dimensional Fund Advisors LP	28,570	$0.26M	0.0%	N/A	0.413%
8/11/2021	Deutsche Bank AG	57,368	$0.52M	0.0%	+51.0%	0.829%
8/2/2021	Optimum Investment Advisors	3,000	$27K	0.0%	N/A	0.043%
5/21/2021	Citadel Advisors LLC	10,402	$100K	0.0%	N/A	0.150%
5/19/2021	Diametric Capital LP	26,328	$0.25M	0.2%	N/A	0.381%
5/18/2021	Morgan Stanley	425,312	$4.09M	0.0%	+1.1%	6.150%
5/18/2021	Perritt Capital Management Inc.	20,000	$0.19M	0.1%	N/A	0.289%
5/18/2021	Citadel Advisors LLC	10,402	$100K	0.0%	N/A	0.150%
5/17/2021	PDT Partners LLC	11,800	$0.11M	0.0%	N/A	0.171%
5/14/2021	Cooper Creek Partners Management LLC	38,197	$0.37M	0.1%	N/A	0.552%
5/13/2021	Renaissance Technologies LLC	145,213	$1.40M	0.0%	-12.1%	2.100%
5/13/2021	Knott David M	58,108	$0.56M	0.2%	-27.5%	0.840%
5/12/2021	Geode Capital Management LLC	21,872	$0.21M	0.0%	+57.3%	0.316%
5/11/2021	Acadian Asset Management LLC	16,950	$0.16M	0.0%	+86.8%	0.246%
2/10/2021	Renaissance Technologies LLC	165,207	$0.70M	0.0%	+39.3%	3.219%
12/30/2020	Deerfield Management Company L.P. Series C	68,413	$0.33M	0.0%	N/A	1.333%
2/20/2020	Geode Capital Management LLC	10,279	$77K	0.0%	-93.0%	0.207%

Data available starting January 2016

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Today's Range

Now: $3.65

$3.43

$3.78

50 Day Range

MA: $3.74

$3.31

$4.21

52 Week Range

Now: $3.65

$1.56

$4.38

Volume

143,580 shs

Average Volume

32,297 shs

Market Capitalization

$191.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Who are the company insiders with the largest holdings of Alimera Sciences?: Alimera Sciences' top insider investors include:
Caligan Partners Lp (Major Shareholder)
Adam Morgan (Director)
Alto Investors Lp Palo (Major Shareholder)
Learn More about top insider investors at Alimera Sciences.
Who are the major institutional investors of Alimera Sciences?: Alimera Sciences' top institutional investors include:
Fifth Lane Capital LP — 0.04%
Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of Alimera Sciences stock.
Which major investors are buying Alimera Sciences stock?: During the previous quarter, ALIM stock was purchased by institutional investors including:
Fifth Lane Capital LP
During the previous year, these company insiders have bought Alimera Sciences stock:
Caligan Partners Lp (Major Shareholder)
Adam Morgan (Director)
Learn More investors buying Alimera Sciences stock.

55x Gains Instead of 9x Gains

From Weiss Ratings | Ad